Description

Aurobindo Pharma Limited, an Indian pharmaceutical enterprise established in 1986 and based in Hyderabad, operates across the entire spectrum of drug development and supply. The company's primary focus involves the discovery, creation, production, and distribution of active pharmaceutical ingredients (APIs), generic medications, and associated support services. Its diverse product lineup encompasses solid oral dosage forms, injectable drugs, and over-the-counter (OTC) remedies. Additionally, it provides essential APIs and finished drug formulations for treating a wide array of medical conditions. These therapeutic categories include cardiovascular illnesses, central nervous system disorders, gastrointestinal complaints, allergies, diabetes, anti-retroviral treatments, various infections, dermatological issues, respiratory conditions, and oncology. Looking ahead, Aurobindo Pharma is actively expanding its research and development efforts into emerging fields. It is building a robust pipeline in biosimilars and vaccines, while also offering tailored research and manufacturing solutions for the biotechnology and pharmaceutical sectors. The company is further engaged in crafting peptides and biocatalysts, vital components for both the pharmaceutical and chemical industries. Its ongoing development initiatives also span inhalers, transdermal patches, topical preparations, and long-acting depot injections. The firm boasts a significant global presence, exporting its products and serving various international corporations. Notably, Aurobindo Pharma has partnered with COVAXX to co-develop and commercialize a COVID-19 vaccine specifically for the Indian market and UNICEF.